Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Can-Fite Biopharma Ltd ADR
(NY:
CANF
)
2.380
+0.140 (+6.25%)
Official Closing Price
Updated: 8:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Can-Fite Biopharma Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
June 30, 2022
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical...
Via
Benzinga
Aspen Aerogels And 28 Stocks Moving Premarket
June 30, 2022
Gainers
Via
Benzinga
Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial
June 29, 2022
Via
Benzinga
Can Fite Biofarma: Q1 Earnings Insights
May 26, 2022
Can Fite Biofarma (AMEX:CANF) reported its Q1 earnings results on Thursday, May 26, 2022. Here's what investors need to know about the announcement.
Via
Benzinga
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
June 30, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
Via
Benzinga
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
June 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
June 29, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
June 24, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
June 09, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2
May 26, 2022
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1...
Via
Benzinga
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
May 26, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Granted Key NASH Patent in Israel
May 16, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
May 02, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?
April 12, 2022
Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
April 05, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
March 28, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports Revenue Growth In 2021, Provides Clinical Update
March 24, 2022
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI) announced
Via
Benzinga
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
March 24, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Can-Fite Reports 2021 Financial Results & Provides Clinical Update
March 24, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
March 14, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX
March 11, 2022
Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF)...
Via
Benzinga
Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study
March 08, 2022
Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson...
Via
Benzinga
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
February 03, 2022
Photo by Diana Polekhina on Unsplash
Via
Benzinga
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
January 31, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
A New Oral Therapy for Psoriasis Could Be Coming Soon
January 24, 2022
Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice...
Via
Benzinga
Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows
January 13, 2022
Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin...
Via
Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
January 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...
Via
Benzinga
PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO
January 13, 2022
Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American:...
Via
Benzinga
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
January 13, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
January 10, 2022
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.